[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"repetitive-transcranial-magnetic-stimulation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:repetitive-transcranial-magnetic-stimulation":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,68,99],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100606312","single-center-double-blind-randomized-placebo-controlled-study-on-efficacy-and-safety-of-rtms-with-precise-localization-in-relieving-motor-symptoms-of-td-100606312",false,"NCT07173920","Single-Center, Double-Blind, Randomized, Placebo-Controlled Study on Efficacy and Safety of rTMS (With Precise Localization) in Relieving Motor Symptoms of TD","A Single-Center, Double-Blind, Randomized, Placebo-Controlled Clinical Study on the Efficacy and Safety of Repetitive Transcranial Magnetic Stimulation (rTMS) Under Precise Localization for Relieving Motor Symptoms of Tardive Dyskinesia","Inclusion Criteria:\n\n* (1) Age between 18 and 65 years; (2) Patients whose diagnosis is consistent with the tardive dyskinesia (TD) diagnostic criteria defined by the Schooler-Kane criteria, with a disease duration of at least 3 months before screening, and a history of treatment with dopamine receptor antagonists for at least 3 months (a minimum of 1 month for patients aged ≥ 60 years); other diseases that may cause involuntary movements are excluded\n\nExclusion Criteria:(1) Diagnosed with movement disorders other than tardive dyskinesia (TD); (2) A history of focal brain injury or severe leukoencephalopathy (Fazekas grade 3 or higher) identified on previous head MRI\u002FCT; (3) A personal history of epilepsy, unexplained loss of consciousness, or current use of anticonvulsant medications for seizure management; (4) Presence of metallic medical devices in the body (e.g., cardiac pacemakers, cochlear implants), other metallic foreign bodies, or any electronic devices implanted in the body; or having other contraindications to repetitive Transcranial Magnetic Stimulation (rTMS); (5) Presence of contraindications to MRI scanning, such as having metallic implants in the body or claustrophobia\n\n\\-","ALL","18 Years","65 Years",{"count":20,"type":21},62,"ESTIMATED","INTERVENTIONAL",[24],"NA","\\# Brief Summary (English Version) Tardive Dyskinesia (TD) is a hyperkinetic movement disorder induced by long-term use of dopamine receptor blockers and related drugs. Characterized by involuntary spasms or choreiform movements involving the tongue, lower face, jaw, and limbs (persisting for at least several weeks), TD causes irreversible neurological damage that persists even after discontinuing the causative drugs, significantly impairing patients' functional outcomes.\n\nrTMS is a non-invasive neuromodulation technique: time-varying currents in a coil generate magnetic fields that penetrate the scalp and skull to act on brain neurons, inducing depolarization, neural network activation, neurotransmitter release, metabolic changes, and gene expression, thereby producing physiological effects \\[9\\]. In recent years, rTMS has gained attention for treating movement disorders (e.g., Parkinson's disease, motor neuron disease, dystonia, essential tremor, Huntington's disease) due to its non-invasiveness, high safety, and repeatability. Studies have reported that rTMS can significantly improve motor symptoms in TD patients \\[10, 11\\]; however, existing research is limited by small sample sizes, conventional treatment parameters, large inter-individual variability, and unclear long-term efficacy.\n\nrTMS efficacy in TD is strongly influenced by parameters including stimulation targets, localization methods, sequences, and cycles. Optical navigation (using personalized MRI) is the most accurate and yields the best therapeutic effects, compared to manual localization or positioning caps . Regarding stimulation sequences, 1Hz and 20Hz rTMS have shown efficacy but with short-lived effects. Continuous theta-Burst Stimulation (cTBS)-a specialized rTMS mode that delivers rapid pulse trains mimicking endogenous theta-wave bursts-provides higher therapeutic doses in less time, enabling more durable efficacy and effectively reducing motor cortex excitability .\n\nTherefore, this study aims to investigate the effect of cTBS (under precise localization) on improving motor symptoms in patients with TD.",[27,28],"Tardive Dyskinesia","Repetitive Transcranial Magnetic Stimulation","RECRUITING","2025-11-27",{"date":32,"type":33},"2025-12-05","ACTUAL",{"date":35,"type":33},"2025-09-08",{"date":37,"type":21},"2028-12-30",{"name":39,"class":40},"Peking University Sixth Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":41},"100574300","lf-rtms-attenuates-visceral-pain-in-irritable-bowel-syndrome-with-diarrhea-100574300","NCT06757491","Lf-rTMS Attenuates Visceral Pain in Irritable Bowel Syndrome With Diarrhea","Low-frequency Repetitive Transcranial Magnetic Stimulation Attenuates Visceral Pain in Irritable Bowel Syndrome With Diarrhea Via Inhibition of the Medial Prefrontal Cortex","All diagnoses were made by board-certified gastroenterologists. Eligible participants met the following inclusion criteria: (1) age between 18 and 75 years; (2) fulfillment of the Rome IV diagnostic criteria for IBS-D. Exclusion criteria included: (1) presence of inflammatory or other organic gastrointestinal diseases; (2) diagnosed psychiatric disorders; (3) history of anorectal, intestinal, or abdominal surgery; (4) pregnancy or lactation; (5) presence of metallic implants or cardiac pacemakers.","75 Years",{"count":51,"type":21},42,[24],"Objectives: To identify a central hub of visceral pain in IBS-D and elucidate the mechanism by which repetitive transcranial magnetic stimulation (rTMS) confers analgesic effects.\n\nMethods: A total of 42 IBS-D patients were recruited and randomly assigned (1:1) to the sham rTMS or the rTMS group. A nested cohort of 21 IBS-D participants who completed baseline fMRI assessments prior to randomization was included. Consistent with the randomization procedure，these individuals were evenly distributed between the two groups. Both participants and outcome assessors remained blinded to treatment allocation throughout the study. All patients completed the two-week intervention and were included in the final analysis.",[28,55,56,57,58],"Chronic Visceral Pain","Functional Magnetic Resonance Imaging","IBS (Irritable Bowel Syndrome)","Clinical Efficacy","2025-11-18",{"date":61,"type":33},"2025-11-21",{"date":63,"type":33},"2024-08-01",{"date":65,"type":21},"2026-01-25",{"name":67,"class":40},"The First Affiliated Hospital of Soochow University",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":84,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100553181","repetitive-transcranial-magnetic-stimulation-and-postoperative-neurocognitive-recovery-100553181","NCT06482749","Repetitive Transcranial Magnetic Stimulation and Postoperative Neurocognitive Recovery","Impact of Repetitive Transcranial Magnetic Stimulation on Postoperative Neurocognitive Recovery in Older Patients With Preoperative Cognitive Impairment: A Randomized, Double-blinded, Sham-controlled Trial","Inclusion Criteria:\n\n1. Aged ≥65 years;\n2. Patients with preoperative mild to moderate cognitive impairment, defined as 9\\\u003CMontreal Cognitive Assessment (MoCA)\\\u003C26;\n3. Scheduled for elective non-cardiac surgery under general anesthesia, with an expected surgical duration of \\>2 hours;\n4. Expected to stay in hospital for at least 5 days after surgery.\n\nExclusion Criteria:\n\n1. Left-handed;\n2. Primary school education level or below;\n3. Comorbid diseases including mental illness, intellectual disability, auditory and visual dysfunction, language impairment, severe neurological disorders, or other diseases that impede the completion of evaluation;\n4. Neurosurgery;\n5. Presence of contraindications to rTMS treatment, including epilepsy, pregnant or lactating women, or with a metal or electric implanted device (e.g., deep brain stimulator, ventriculoperitoneal shunt, aneurysm clip, pacemaker, cochlear implant, or surgical staples on the scalp);\n6. Other situations that are deemed unsuitable for inclusion in the study.",{"count":76,"type":21},568,[24],"Patients with preoperative cognitive impairment are at increased risks of delayed neurocognitive recovery (DNR) and postoperative neurocognitive disorder (POCD). Repetitive transcranial magnetic stimulation (rTMS) has been used to improve cognitive function in patients with cognitive impairement. This trial is designed to compare the effects of rTMS versus sham intervention on postoperative neurocognitive function in patients with preoperative cognitive impairment.",[80,81,28,82,83],"Older Patients","Cognitive Impairment","Delayed Neurocognitive Recovery","Postoperative Neurocognitive Disorder",[85,86,87,88,89],"Older patients","Cognitive impairment","Repetitive transcranial magnetic stimulation","Delayed neurocognitive recovery","Postoperative neurocognitive disorder","2025-07-28",{"date":92,"type":33},"2025-07-31",{"date":90,"type":33},{"date":95,"type":21},"2029-02",{"name":97,"class":40},"Peking University First Hospital",3,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":106,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":4},"100577516","comparative-effectiveness-of-ipsilesional-high-frequency-rtms-contralesional-continuous-burst-theta-rtms-and-sham-rtms-each-combined-with-physiotherapy-in-subacute-ischemic-stroke-upper-limb-recovery--clinical-neurophysiological-and-radiological-100577516","NCT06799312","Comparative Effectiveness of Ipsilesional High-frequency rTMS, Contralesional Continuous Burst Theta rTMS, and Sham rTMS, Each Combined With Physiotherapy, in Subacute Ischemic Stroke Upper Limb Recovery : Clinical, Neurophysiological and Radiological","Comparative Effectiveness of Ipsilesional High-frequency rTMS, Contralesional Continuous Burst Theta rTMS, and Sham rTMS, Each Combined With Physiotherapy, in Subacute Ischemic Stroke Upper Limb Recovery : Clinical, Neurophysiological and Radiological: A Double-blinded Randomized Clinical Trial","Inclusion Criteria:\n\n* First-ever ischemic stroke, confirmed by imaging.\n* Stroke affecting the non-dominant hemisphere (cortical or subcortical) within the middle cerebral artery (MCA) territory.\n* Acute to subacute stage of stroke (time since onset: 48 hours to 2 weeks).\n* Ability to comply with the study protocol and interventions.\n\nExclusion Criteria:\n\n* Hemorrhagic stroke or bilateral stroke.\n* Severe cognitive impairment, defined as a Montreal Cognitive Assessment (MoCA) score \\\u003C 10.\n* Contraindications to TMS, such as: History of epilepsy, Metallic implants in the head, Other contraindications based on TMS safety guidelines.\n* Comorbid conditions that limit participation in rehabilitation.\n* Severe neglect or aphasia that would impede participation in therapy.","40 Years","70 Years",{"count":109,"type":21},90,[24],"To compare the efficacy of lesional high-frequency rTMS, contralesional cTBS, and sham stimulation in improving motor and cognitive recovery in post-stroke patients undergoing physiotherapy.",[28,113,114],"Stroke","Functional MRI","NOT_YET_RECRUITING","2025-03-02",{"date":118,"type":33},"2025-03-05",{"date":120,"type":21},"2025-03-15",{"date":122,"type":21},"2026-12-31",{"name":124,"class":40},"Assiut University"]